SCHEMBL30128566

SCHEMBL30128566

Nc1ncccc1-c1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.59
MKNK2 Q9HBH9 1/20 0.59
MAP4K4 O95819 10/20 0.55
CYP1A2 P05177 2/20 0.49
KCNH2 Q12809 1/20 0.49
MINK1 Q8N4C8 1/20 0.49
TNIK Q9UKE5 1/20 0.49
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
TDO2 P48775 1/20 0.43
GLO1 Q04760 1/20 0.42
NOS3 P29474 1/20 0.42
NOS1 P29475 1/20 0.42
NOS2 P35228 1/20 0.42
PTGS1 P23219 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623411 0.82 MAP4K4 (0.61) MKNK1MKNK2MAP4K4KDM4EALDH1A1
SCHEMBL1148699 0.81 MAP4K4 (0.66) MKNK1MKNK2MAP4K4ALDH1A1TDO2
SCHEMBL4582566 0.80 MKNK1 (0.59) MKNK1MKNK2MAP4K4NOS3NOS1
SCHEMBL26071485 0.80 MKNK1 (0.59) MKNK1MKNK2MAP4K4CYP1A2KDM4E
SCHEMBL2253189 0.80 MKNK1 (0.59) MKNK1MKNK2MAP4K4CYP1A2KDM4E
SCHEMBL4582572 0.80 MKNK1 (0.59) MKNK1MKNK2MAP4K4KDM4EALDH1A1
SCHEMBL624668 0.80 MKNK1 (0.64) MKNK1MKNK2MAP4K4NOS3NOS1
SCHEMBL624495 0.79 MKNK1 (0.54) MKNK1MKNK2MAP4K4KDM4EALDH1A1
SCHEMBL11127668 0.79 MAP4K4 (0.58) MKNK1MKNK2MAP4K4TDO2NOS3
SCHEMBL29442167 0.79 MAP4K4 (0.58) MKNK1MKNK2MAP4K4TDO2NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234224-B2 Pyrimidine and pyridine amine compounds and usage thereof in disease treatment EPIGEN BIOSCIENCES, INC. (US) 2025-02-25 US disclosed
US-20240124423-A1 PYRIMIDINE AND PYRIDINE AMINE COMPOUNDS AND USAGE THEREOF IN DISEASE TREATMENT EPIGEN BIOSCIENCES, INC. (US) 2024-04-18 US disclosed
US-11866421-B2 Pyrimidine and pyridine amine compounds and usage thereof in disease treatment EPIGEN BIOSCIENCES, INC. (US) 2024-01-09 US disclosed
US-20220396564-A1 PYRIMIDINE AND PYRIDINE AMINE COMPOUNDS AND USAGE THEREOF IN DISEASE TREATMENT EPIGEN BIOSCIENCES, INC. (US) 2022-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12234224-B2 Pyrimidine and pyridine amine compounds and usage thereof in disease treatment PDXK, RPS6KA6, RPS6KA4 MKNK1 113/4885MKNK2 194/4885MAP4K4 119/4885
US-20220396564-A1 PYRIMIDINE AND PYRIDINE AMINE COMPOUNDS AND USAGE THEREOF IN DISEASE TREATMENT PDXK, RPS6KA6, RPS6KA4 MKNK1 113/4885MKNK2 194/4885MAP4K4 119/4885
US-20240124423-A1 PYRIMIDINE AND PYRIDINE AMINE COMPOUNDS AND USAGE THEREOF IN DISEASE TREATMENT PDXK, RPS6KA6, RPS6KA4 MKNK1 113/4885MKNK2 194/4885MAP4K4 119/4885
US-11866421-B2 Pyrimidine and pyridine amine compounds and usage thereof in disease treatment PDXK, RPS6KA6, RPS6KA4 MKNK1 113/4885MKNK2 194/4885MAP4K4 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.